FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050433366> ?p ?o ?g. }

• W2050433366 endingPage "420" @default.
• W2050433366 startingPage "412" @default.
• W2050433366 abstract "BackgroundAllergen-specific immunotherapy is the only causative treatment of IgE-mediated allergic disorders. The most common administration route is subcutaneous, which may necessitate more than 50 allergen injections during 3 to 5 years. Recent evidence suggests that direct intralymphatic injections could yield faster beneficial results with considerably lower allergen doses and markedly reduced numbers of injections.ObjectiveTo evaluate the effects of intralymphatic allergen-specific immunotherapy in pollen-allergic patients.MethodsIn an open pilot investigation followed by a double-blind, placebo-controlled study, patients with allergic rhinitis were treated with 3 intralymphatic inguinal injections of ALK Alutard (containing 1000 SQ-U birch pollen or grass pollen) or placebo (ALK diluent). Clinical pre- and posttreatment parameters were assessed, the inflammatory cell content in nasal lavage fluids estimated, and the activation pattern of peripheral T cells described.ResultsAll patients tolerated the intralymphatic immunotherapy (ILIT) treatment well, and the injections did not elicit any severe adverse event. Patients receiving active treatment displayed an initial increase in allergen-specific IgE level and peripheral T-cell activation. A clinical improvement in nasal allergic symptoms upon challenge was recorded along with a decreased inflammatory response in the nose. In addition, these patients reported an improvement in their seasonal allergic disease. No such changes were seen in the placebo group.ConclusionsAlthough this study is based on a limited number of patients, ILIT with grass-pollen or birch-pollen extracts appears to reduce nasal allergic symptoms without causing any safety problems. Hence, ILIT might constitute a less time-consuming and more cost-effective alternative to conventional subcutaneous allergen-specific immunotherapy. Allergen-specific immunotherapy is the only causative treatment of IgE-mediated allergic disorders. The most common administration route is subcutaneous, which may necessitate more than 50 allergen injections during 3 to 5 years. Recent evidence suggests that direct intralymphatic injections could yield faster beneficial results with considerably lower allergen doses and markedly reduced numbers of injections. To evaluate the effects of intralymphatic allergen-specific immunotherapy in pollen-allergic patients. In an open pilot investigation followed by a double-blind, placebo-controlled study, patients with allergic rhinitis were treated with 3 intralymphatic inguinal injections of ALK Alutard (containing 1000 SQ-U birch pollen or grass pollen) or placebo (ALK diluent). Clinical pre- and posttreatment parameters were assessed, the inflammatory cell content in nasal lavage fluids estimated, and the activation pattern of peripheral T cells described. All patients tolerated the intralymphatic immunotherapy (ILIT) treatment well, and the injections did not elicit any severe adverse event. Patients receiving active treatment displayed an initial increase in allergen-specific IgE level and peripheral T-cell activation. A clinical improvement in nasal allergic symptoms upon challenge was recorded along with a decreased inflammatory response in the nose. In addition, these patients reported an improvement in their seasonal allergic disease. No such changes were seen in the placebo group. Although this study is based on a limited number of patients, ILIT with grass-pollen or birch-pollen extracts appears to reduce nasal allergic symptoms without causing any safety problems. Hence, ILIT might constitute a less time-consuming and more cost-effective alternative to conventional subcutaneous allergen-specific immunotherapy." @default.
• W2050433366 created "2016-06-24" @default.
• W2050433366 creator A5035165090 @default.
• W2050433366 creator A5038992948 @default.
• W2050433366 creator A5063502069 @default.
• W2050433366 creator A5073813513 @default.
• W2050433366 date "2013-02-01" @default.
• W2050433366 modified "2023-10-18" @default.
• W2050433366 title "Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for pollen-induced allergic rhinitis" @default.
• W2050433366 cites W1657102408 @default.
• W2050433366 cites W1725440630 @default.
• W2050433366 cites W1943997503 @default.
• W2050433366 cites W1963675962 @default.
• W2050433366 cites W1970877567 @default.
• W2050433366 cites W1974574903 @default.
• W2050433366 cites W1974915236 @default.
• W2050433366 cites W1975755712 @default.
• W2050433366 cites W1977316399 @default.
• W2050433366 cites W2003444408 @default.
• W2050433366 cites W2016895195 @default.
• W2050433366 cites W2019276583 @default.
• W2050433366 cites W2020503655 @default.
• W2050433366 cites W2022429437 @default.
• W2050433366 cites W2029073858 @default.
• W2050433366 cites W2029226756 @default.
• W2050433366 cites W2029420818 @default.
• W2050433366 cites W2032199331 @default.
• W2050433366 cites W2033232206 @default.
• W2050433366 cites W2052063445 @default.
• W2050433366 cites W2052122855 @default.
• W2050433366 cites W2057868114 @default.
• W2050433366 cites W2058014154 @default.
• W2050433366 cites W2061178990 @default.
• W2050433366 cites W2065006357 @default.
• W2050433366 cites W2065917693 @default.
• W2050433366 cites W2066211228 @default.
• W2050433366 cites W2070033188 @default.
• W2050433366 cites W2073231491 @default.
• W2050433366 cites W2112571043 @default.
• W2050433366 cites W2130614990 @default.
• W2050433366 cites W2140430665 @default.
• W2050433366 cites W2141907699 @default.
• W2050433366 cites W2143918423 @default.
• W2050433366 cites W2164132449 @default.
• W2050433366 cites W2925184086 @default.
• W2050433366 cites W4240430066 @default.
• W2050433366 cites W4251809502 @default.
• W2050433366 doi "https://doi.org/10.1016/j.jaci.2012.10.056" @default.
• W2050433366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23374268" @default.
• W2050433366 hasPublicationYear "2013" @default.
• W2050433366 type Work @default.
• W2050433366 sameAs 2050433366 @default.
• W2050433366 citedByCount "117" @default.
• W2050433366 countsByYear W20504333662012 @default.
• W2050433366 countsByYear W20504333662013 @default.
• W2050433366 countsByYear W20504333662014 @default.
• W2050433366 countsByYear W20504333662015 @default.
• W2050433366 countsByYear W20504333662016 @default.
• W2050433366 countsByYear W20504333662017 @default.
• W2050433366 countsByYear W20504333662018 @default.
• W2050433366 countsByYear W20504333662019 @default.
• W2050433366 countsByYear W20504333662020 @default.
• W2050433366 countsByYear W20504333662021 @default.
• W2050433366 countsByYear W20504333662022 @default.
• W2050433366 countsByYear W20504333662023 @default.
• W2050433366 crossrefType "journal-article" @default.
• W2050433366 hasAuthorship W2050433366A5035165090 @default.
• W2050433366 hasAuthorship W2050433366A5038992948 @default.
• W2050433366 hasAuthorship W2050433366A5063502069 @default.
• W2050433366 hasAuthorship W2050433366A5073813513 @default.
• W2050433366 hasBestOaLocation W20504333661 @default.
• W2050433366 hasConcept C126322002 @default.
• W2050433366 hasConcept C141071460 @default.
• W2050433366 hasConcept C141105273 @default.
• W2050433366 hasConcept C142724271 @default.
• W2050433366 hasConcept C159654299 @default.
• W2050433366 hasConcept C170493617 @default.
• W2050433366 hasConcept C197934379 @default.
• W2050433366 hasConcept C203014093 @default.
• W2050433366 hasConcept C204787440 @default.
• W2050433366 hasConcept C207480886 @default.
• W2050433366 hasConcept C27081682 @default.
• W2050433366 hasConcept C2777701055 @default.
• W2050433366 hasConcept C2778311950 @default.
• W2050433366 hasConcept C2779779143 @default.
• W2050433366 hasConcept C2779787640 @default.
• W2050433366 hasConcept C2780510475 @default.
• W2050433366 hasConcept C71924100 @default.
• W2050433366 hasConcept C8891405 @default.
• W2050433366 hasConceptScore W2050433366C126322002 @default.
• W2050433366 hasConceptScore W2050433366C141071460 @default.
• W2050433366 hasConceptScore W2050433366C141105273 @default.
• W2050433366 hasConceptScore W2050433366C142724271 @default.
• W2050433366 hasConceptScore W2050433366C159654299 @default.
• W2050433366 hasConceptScore W2050433366C170493617 @default.
• W2050433366 hasConceptScore W2050433366C197934379 @default.
• W2050433366 hasConceptScore W2050433366C203014093 @default.
• W2050433366 hasConceptScore W2050433366C204787440 @default.

• next